Glucagon-like peptide (GLP)-1 receptor (GLP1R) agonists exert a multitude of beneficial cardiovascular effects beyond control of blood glucose levels and obesity reduction. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.